---
title: MDA
description: 
published: true
date: 2026-01-30T09:32:40.602Z
tags: 
editor: markdown
dateCreated: 2026-01-30T05:55:42.443Z
---

[â—€è¿”å›](./home.md)


# MDA

</mark> è¿˜å¥½<mark>

| MDA | |
| --- | --- |
| [![MDA.svg](./../æ–‡ä»¶/MDA.svg)](./../æ–‡ä»¶/MDA.svg) | |
| åŒ–å­¦å‘½åæ³• | |
| å¸¸ç”¨å | *MDA, Sass, Sally, Tenamfetamine* |
| å–ä»£åç§° | *3,4\-äºšç”²åŒæ°§åŸºè‹¯ä¸™èƒº* |
| ç³»ç»Ÿåç§° | *(R) 1\-(benzo\[1,3\]dioxol\-5\-yl)propan\-2\-amine* |
| ç±»åˆ«å½’å± | |
| ç²¾ç¥æ´»æ€§ç±»åˆ« | *[å…±æƒ…å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogen") / [å…´å¥‹å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant") / [è‡´å¹»å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‡´å¹»å‰‚.md "Psychedelic")* |
| åŒ–å­¦ç±»åˆ« | *[è‹¯ä¸™èƒº](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¸™èƒºç±»ç‰©è´¨.md "Substituted amphetamine") / [MDxx](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/äºšç”²åŒæ°§åŸºè‹¯ç±»ç‰©è´¨.md "MDxx")* |
| [ç»™è¯é€”å¾„](./../æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of Administration") | |
| - **è­¦å‘Šï¼š** ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€æ–°é™ˆä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»ä½å‰‚é‡å¼€å§‹ã€‚[è¯·å‚é˜…è´Ÿè´£ä»»çš„ç”¨è¯éƒ¨åˆ†](./../æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible drug use")ã€‚ <br>   <br>    | â‡£ [å£æœ](./../æ–‡æ¡£/ç»™è¯é€”å¾„.md#å£æœ "Routes of Administration") | | | --- | --- | | [ç»™è¯å‰‚é‡](./../æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage") | | | | [é˜ˆå€¼](./../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#é˜ˆå€¼ "Dosage classification") | 20 mg | | [è½»å¾®](./../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#è½»å¾® "Dosage classification") | 40 \- 60 mg | | [ä¸­ç­‰](./../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#ä¸­ç­‰ "Dosage classification") | 60 \- 100 mg | | [å¼ºçƒˆ](./../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#å¼ºçƒˆ "Dosage classification") | 100 \- 145 mg | | [ä¸¥é‡](./../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#ä¸¥é‡ "Dosage classification") | 145 mg \+ | | [è¯æ•ˆæ—¶é•¿](./../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | | | [æ€»æ—¶é•¿](./../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#æ€»æ—¶é•¿ "Duration") | 5 \- 8 å°æ—¶ | | [è¯æ•ˆå‘ä½œ](./../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#è¯æ•ˆå‘ä½œ "Duration") | 30 \- 90 åˆ†é’Ÿ | | [è¯æ•ˆä¸Šå‡](./../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#è¯æ•ˆä¸Šå‡ "Duration") | 15 \- 45 åˆ†é’Ÿ | | [è¯æ•ˆè¾¾å³°](./../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#è¯æ•ˆè¾¾å³° "Duration") | 2\.5 \- 4 å°æ—¶ | | [è¯æ•ˆè¤ªå»](./../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#è¯æ•ˆè¤ªå» "Duration") | 2 \- 3 å°æ—¶ | | [è¯æ•ˆæ®‹ä½™](./../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#è¯æ•ˆæ®‹ä½™ "Duration") | 4 \- 48 å°æ—¶ | <br>   <br>   <br>   <br>   <br>   <br>   <br>   <br>    - **[å…è´£å£°æ˜](./../æ–‡æ¡£/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md "Disclaimer"):** æœ¬ç«™çš„[ç»™è¯å‰‚é‡](./../æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage")ä¿¡æ¯æ”¶é›†è‡ªç”¨æˆ·å’Œ[èµ„æº](./../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md "Network")ï¼Œä»…ä¾›æ•™è‚²ç›®çš„ã€‚è¿™å¹¶éæ¨èï¼Œåº”ä¸å…¶ä»–æ¥æºæ ¸å®ä»¥ç¡®ä¿å‡†ç¡®æ€§ã€‚ | |
| [ç›¸äº’ä½œç”¨](#Dangerous_interactions) | |
| [é…’ç²¾](./é…’ç²¾.md) | âš ï¸ è°¨æ…è”ç”¨ |
| [MXE](./3-MeO-PCE.md) | ğŸ’” è”ç”¨å±é™© |
| [è§£ç¦»å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md) | ğŸ’” è”ç”¨å±é™© |
| [å³ç¾æ²™èŠ¬](./å³ç¾æ²™èŠ¬.md) | â›” ä¸¥ç¦è”ç”¨ |
| [MDMA](./MDMA.md) | ğŸ’” è”ç”¨å±é™© |
| [å…´å¥‹å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md) | ğŸ’” è”ç”¨å±é™© |
| [25x\-NBOMe](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/2,5-äºŒç”²æ°§åŸºè‹¯ä¹™èƒºç±»ç‰©è´¨.md) | â›” ä¸¥ç¦è”ç”¨ |
| [25x\-NBOH](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/2,5-äºŒç”²æ°§åŸºè‹¯ä¹™èƒºç±»ç‰©è´¨.md) | â›” ä¸¥ç¦è”ç”¨ |
| [æ›²é©¬å¤š](./æ›²é©¬å¤š.md) | â›” ä¸¥ç¦è”ç”¨ |
| SNRIs | ğŸ’” è”ç”¨å±é™© |
| [MAOIs](./../æ–‡æ¡£/å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚.md) | â›” ä¸¥ç¦è”ç”¨ |
| [ç¥ç»é€’è´¨é‡Šæ”¾å‰‚](./../æ–‡æ¡£/ç¥ç»é€’è´¨é‡Šæ”¾å‰‚.md) | â›” ä¸¥ç¦è”ç”¨ |
| SSRIs | ğŸ’” è”ç”¨å±é™© |
| 5\-HTP | â›” ä¸¥ç¦è”ç”¨ |



**3,4\-äºšç”²åŒæ°§åŸºè‹¯ä¸™èƒº** (ä¹Ÿç§°ä¸º **MDA**, å’Œ **Tenamfetamine**, æˆ–ä¿—ç§°ä¸º **"Sally"**, **"Sass"**, æˆ– **"Sass\-a\-frass"**) æ˜¯ä¸€ç§[è‹¯ä¸™èƒº](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¸™èƒºç±»ç‰©è´¨.md "Amphetamine")ç±»çš„åˆæˆ[å…±æƒ…å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogen")ã€‚å½“[ç»™è¯](./../æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of administration")æ—¶ï¼Œå®ƒä¼šäº§ç”ŸæŒä¹…çš„[å…±æƒ…](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogenic")ã€[å…´å¥‹å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")å’Œè½»å¾®çš„[è¿·å¹»](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Psychedelic")æ•ˆåº”ï¼ŒåŒ…æ‹¬[åˆºæ¿€](./../è¯æ•ˆ/åˆºæ¿€.md "Stimulation")ã€[ç„¦è™‘æŠ‘åˆ¶](./../è¯æ•ˆ/é•‡é™.md "Anxiety suppression")ã€[å¢å¼ºçš„åŒç†å¿ƒã€æƒ…æ„Ÿå’Œç¤¾äº¤èƒ½åŠ›](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Empathy, affection, and sociability enhancement")ï¼Œä»¥åŠ[æ¬£å¿«æ„Ÿ](./../è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md "Euphoria")ã€‚

MDA äº 1910 å¹´é¦–æ¬¡åˆæˆï¼Œä½†åœ¨ 1930 å¹´æ‰å‘ç°å…¶ç²¾ç¥æ´»æ€§æ•ˆåº”ã€‚å®ƒåœ¨ 1939 å¹´è‡³ 1941 å¹´ä»¥åŠ 1949 å¹´è‡³ 1957 å¹´é—´ç”¨äºåŠ¨ç‰©å’Œäººä½“è¯•éªŒã€‚åœ¨ä¸€é¡¹è°ƒæŸ¥å…¶ä½œä¸º[æŠ—æŠ‘éƒè¯](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Antidepressant")æˆ–[åŒé£Ÿè¯](./../è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md "Appetite suppression")çš„æ½œåœ¨ç”¨é€”çš„ç ”ç©¶ä¸­ï¼Œè¶…è¿‡ 500 åäººç±»å—è¯•è€…æœç”¨äº† MDAã€‚[\[1\]](#cite_note-Mannich1910-1) åˆ° 1958 å¹´ï¼Œå®ƒæˆåŠŸç”³è¯·äº†ä½œä¸º[å’³å—½æŠ‘åˆ¶å‰‚](./../è¯æ•ˆ/å’³å—½æŠ‘åˆ¶.md "Cough suppression")å’Œå®‰å®šè¯çš„ä¸“åˆ©ã€‚åˆ° 1961 å¹´ï¼Œå®ƒä»¥å•†å“å "Amphedoxamine" ç”³è¯·äº†ä½œä¸º[åŒé£Ÿè¯](./../è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md "Appetite suppression")çš„ä¸“åˆ©ã€‚\[*[éœ€è¦å¼•ç”¨]*\]

å½“ä»£çš„æŠ¥å‘Šè¡¨æ˜ï¼ŒMDA ä½œä¸ºä¸€ç§å¨±ä¹æ€§è¯ç‰©å‡ºç°äº 1967 å¹´åº•ï¼Œè¿™æ„å‘³ç€å®ƒçš„ä½¿ç”¨æ—©äºå…¶æ›´å¹¿æ³›ä½¿ç”¨çš„äº²å± [MDMA](./MDMA.md "MDMA") (**æ‘‡å¤´ä¸¸**)ã€‚[\[2\]](#cite_note-2)

ä¸ [MDMA](./MDMA.md "MDMA") ä¸€æ ·ï¼ŒMDA è¢«è®¤ä¸ºä¸»è¦ä½œä¸º[è¡€æ¸…ç´ ](./../æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")\-[å»ç”²è‚¾ä¸Šè…ºç´ ](./../æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine")\-[å¤šå·´èƒº](./../æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine")çš„[å†æ‘„å–æŠ‘åˆ¶å‰‚](./../æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Reuptake inhibitor")å’Œ[é‡Šæ”¾å‰‚](./../æ–‡æ¡£/ç¥ç»é€’è´¨é‡Šæ”¾å‰‚.md "Releasing agent")èµ·ä½œç”¨ã€‚\[*[éœ€è¦å¼•ç”¨]*\] ç„¶è€Œï¼Œç›¸å¯¹äº [MDMA](./MDMA.md "MDMA")ï¼ŒMDA æŒ‰é‡é‡è®¡æ•ˆåŠ›æ˜æ˜¾æ›´å¼ºï¼Œä¸»è§‚å¼ºåº¦ä¹Ÿæ›´é«˜ã€‚å®ƒçš„æŒç»­æ—¶é—´ä¹Ÿæ˜æ˜¾æ›´é•¿ï¼ˆ6 åˆ° 8 å°æ—¶ï¼Œè€Œä¸æ˜¯ 3 åˆ° 5 å°æ—¶ï¼‰ï¼Œå¹¶äº§ç”Ÿæ›´ä¼ ç»Ÿçš„[è¡€æ¸…ç´ èƒ½è‡´å¹»å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‡´å¹»å‰‚.md "Serotonergic psychedelic")æ•ˆåº”ï¼ˆå¦‚[è§†è§‰æ‰­æ›²](./../è¯æ•ˆ/è§†è§‰æ‰­æ›².md "Visual effects - Psychedelics")ï¼‰ï¼Œä»¥åŠæ˜æ˜¾æ›´é«˜çš„å¤šå·´èƒºæ´»æ€§ï¼Œè¿™ä¹Ÿè¢«è®¤ä¸ºæ˜¯å¯¼è‡´å…¶äº§ç”Ÿæ›´å¤§ç¨‹åº¦ç¥ç»æ¯’æ€§çš„åŸå› ã€‚[\[3\]](#cite_note-3)

å¦‚ä»Šï¼Œåœ¨å¤§å¤šæ•°å›½å®¶æ‹¥æœ‰ MDA æ˜¯éæ³•çš„ï¼Œå°½ç®¡å­˜åœ¨ä¸€äº›ç”¨äºç§‘å­¦å’ŒåŒ»å­¦ç ”ç©¶çš„æœ‰é™ä¾‹å¤–ã€‚

ç›®å½•
--------

* [1 å†å²ä¸æ–‡åŒ–](#History_and_culture)
* [2 åŒ–å­¦](#Chemistry)
* [3 è¯ç†å­¦](#Pharmacology)
* [4 ä¸»è§‚æ•ˆåº”](#Subjective_effects)
    + [4\.1 **èº¯ä½“æ•ˆåº”**](#Physical_effects)
    + [4\.2 **è§†è§‰æ•ˆåº”**](#Visual_effects)
        - [4\.2\.1 å¢å¼º](#Enhancements)
        - [4\.2\.2 æ‰­æ›²](#Distortions)
        - [4\.2\.3 å‡ ä½•å›¾å½¢](#Geometry)
        - [4\.2\.4 å¹»è§‰çŠ¶æ€](#Hallucinatory_states)
    + [4\.3 **è®¤çŸ¥æ•ˆåº”**](#Cognitive_effects)
    + [4\.4 **å¬è§‰æ•ˆåº”**](#Auditory_effects)
    + [4\.5 **è¶…ä¸ªäººæ•ˆåº”**](#Transpersonal_effects)
    + [4\.6 **è¯æ•ˆæ®‹ä½™**](#After_effects)
    + [4\.7 ä½“éªŒæŠ¥å‘Š](#Experience_reports)
* [5 æ¯’æ€§ä¸å±å®³æ½œåŠ›](#Toxicity_and_harm_potential)
    + [5\.1 è€å—æ€§ä¸æˆç˜¾æ½œåŠ›](#Tolerance_and_addiction_potential)
    + [5\.2 å±é™©çš„ç›¸äº’ä½œç”¨](#Dangerous_interactions)
        - [5\.2\.1 è¡€æ¸…ç´ ç»¼åˆå¾é£é™©](#Serotonin_syndrome_risk)
* [6 æ³•å¾‹åœ°ä½](#Legal_status)
* [7 å¦è§](#See_also)
* [8 å¤–éƒ¨é“¾æ¥](#External_links)
* [9 æ–‡çŒ®](#Literature)
* [10 å‚è€ƒæ–‡çŒ®](#References)

å†å²ä¸æ–‡åŒ–
-------------------

MDA æœ€åˆç”± G. Mannish å’Œ W. Jacobson äº 1910 å¹´åˆæˆã€‚[\[1\]](#cite_note-Mannich1910-1) ç„¶è€Œï¼Œç›´åˆ° 1930 å¹´ 7 æœˆ Gordon Alles è¿›è¡Œè‡ªæˆ‘å®éªŒï¼Œå…¶ç²¾ç¥æ´»æ€§æ•ˆåº”æ‰è¢«å‘ç°ã€‚Alles åæ¥å°†è¯¥è¯ç‰©è®¸å¯ç»™ Smith, Kline & French å…¬å¸ã€‚é¦–æ¬¡åŠ¨ç‰©è¯•éªŒå‘ç”Ÿäº 1939 å¹´ï¼Œéšåäº 1941 å¹´è¿›è¡Œäº†äººä½“è¯•éªŒï¼Œæ¢ç´¢å…¶ä½œä¸ºå¸•é‡‘æ£®ç—…æ²»ç–—æ–¹æ³•çš„å¯èƒ½æ€§ã€‚ä» 1949 å¹´åˆ° 1957 å¹´ï¼ŒSmith, Kline & French å…¬å¸åœ¨ä¸€é¡¹è°ƒæŸ¥ MDA ä½œä¸ºæŠ—æŠ‘éƒè¯å’ŒåŒé£Ÿè¯æ½œåœ¨ç”¨é€”çš„ç ”ç©¶ä¸­ï¼Œå‘ 500 å¤šåäººç±»å—è¯•è€…æä¾›äº† MDAã€‚\[*[éœ€è¦å¼•ç”¨]*\]

ç¾å›½é™†å†›åœ¨å¼€å‘ä¸€ç§è¯šå®è¯æˆ–å¤±èƒ½å‰‚æ—¶ä¹Ÿè¯•éªŒäº†è¿™ç§è¯ç‰©ï¼Œä»£å·ä¸º EA-1298ã€‚ä¸€åå« Harold Blauer çš„ç”·å­åœ¨é™è„‰æ³¨å°„ 450 æ¯«å…‹è¯¥è¯ç‰©åäº 1953 å¹´ 1 æœˆæ­»äº¡ã€‚[\[4\]](#cite_note-4)

MDA æœ€ç»ˆäº 1958 å¹´è¢« H. D. Brown ç”³è¯·ä¸ºå’³å—½æŠ‘åˆ¶å‰‚ä¸“åˆ©ï¼Œäº 1960 å¹´è¢« Smith, Kline & French ç”³è¯·ä¸ºå®‰å®šè¯ä¸“åˆ©ï¼Œå¹¶äº 1961 å¹´ä»¥å•†å“å "Amphedoxamine" ç”³è¯·ä¸ºåŒé£Ÿè¯ä¸“åˆ©ã€‚MDA äº 1967 å¹´å·¦å³å¼€å§‹å‡ºç°åœ¨å¨±ä¹æ€§è¯ç‰©åœºæ™¯ä¸­ã€‚1968 å¹´åˆï¼Œè¯ç‰©æ»¥ç”¨ç®¡åˆ¶å±€æŠ¥å‘Šä»çº½çº¦çš„ä¸€ä¸ªç§˜å¯†å®éªŒå®¤æŸ¥è·äº†è¶…è¿‡ 1.4 å…¬æ–¤çš„ MDA å’Œ 11 å…¬æ–¤çš„å‰ä½“[\[5\]](#cite_note-5)ã€‚

1992 å¹´ï¼Œä¸€å¤§æ‰¹è¢«ç§°ä¸º "Snowballs" çš„è¯ä¸¸åœ¨æ¬§æ´²å¤§é‡æµé€šï¼Œæ„å¤–åœ°å«æœ‰ MDA è€Œä¸æ˜¯ MDMAã€‚è¿™æ‰¹è¯ç‰©å½“å¹´åœ¨è‹±å›½å’Œæ¬§æ´²å¼•å‘äº†ä¸€æ³¢éåŒå¯»å¸¸çš„å¹»è§‰æµªæ½®ï¼Œå› ä¸ºåŒ–å­¦å®¶ç»™è¯ä¸¸æœç”¨çš„æ´»æ€§ç‰©è´¨å‰‚é‡ä¸å‡†ç¡®ï¼Œè¾¾åˆ°äº†è¿‘ 200 æ¯«å…‹ï¼Œè€Œè¿™ç§ç‰©è´¨é€šå¸¸åœ¨è¾ƒä½å‰‚é‡ä¸‹ä½¿ç”¨ã€‚[\[6\]](#cite_note-6)

å‡ ä½ç ”ç©¶äººå‘˜ï¼ŒåŒ…æ‹¬ Claudio Naranjo å’Œ Richard Yensenï¼Œæ¢ç´¢äº†åœ¨å¿ƒç†æ²»ç–—é¢†åŸŸåˆ©ç”¨ MDAã€‚[\[7\]](#cite_note-7)[\[8\]](#cite_note-8) 2010 å¹´ï¼ŒMatthew Baggott åŠå…¶åŒäº‹ç ”ç©¶äº† MDA åœ¨å¥åº·å¿—æ„¿è€…ä¸­å¼•å‘ç¥ç§˜ä½“éªŒå’Œæ”¹å˜è§†è§‰çš„èƒ½åŠ›ã€‚[\[9\]](#cite_note-9)

åŒ–å­¦
---------

MDAï¼Œä¹Ÿç§°ä¸º 3,4-äºšç”²åŒæ°§åŸºè‹¯ä¸™èƒºï¼Œæ˜¯è‹¯ä¸™èƒºå®¶æ—çš„ä¸€ç§åˆæˆåˆ†å­ã€‚è‹¯ä¸™èƒºç±»åˆ†å­åŒ…å«ä¸€ä¸ªè‹¯ä¹™èƒºæ ¸å¿ƒï¼Œè¯¥æ ¸å¿ƒå…·æœ‰ä¸€ä¸ªè‹¯ç¯ï¼Œé€šè¿‡ä¹™åŸºé“¾ä¸æ°¨åŸº (NH2) ç»“åˆï¼Œåœ¨ RÎ± å¤„æœ‰ä¸€ä¸ªé¢å¤–çš„ç”²åŸºå–ä»£ã€‚MDA åœ¨è‹¯ç¯çš„ R3 å’Œ R4 å¤„ä¹Ÿæœ‰æ°§åŸºå›¢å–ä»£ã€‚è¿™äº›æ°§åŸºå›¢é€šè¿‡äºšç”²åŸºé“¾ç»“åˆæˆäºšç”²äºŒæ°§åŸºç¯ã€‚MDA ä¸ [MDMA](./MDMA.md "MDMA")ã€[MDAI](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/äºšç”²åŒæ°§åŸºè‹¯ç±»ç‰©è´¨.md "MDAI") ä»¥åŠæ›´æ¨¡ç³Šçš„å˜ä½“å¦‚ [MDEA](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/äºšç”²åŒæ°§åŸºè‹¯ç±»ç‰©è´¨.md "MDEA") æˆ– MMDA å…±äº«è¿™ä¸ªäºšç”²äºŒæ°§åŸºç¯ã€‚

è¯ç†å­¦
------------

æ›´å¤šä¿¡æ¯ï¼š[è¡€æ¸…ç´ èƒ½è‡´å¹»å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‡´å¹»å‰‚.md "Serotonergic psychedelic")

MDA ä½œä¸ºç¥ç»é€’è´¨[è¡€æ¸…ç´ ](./../æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")ã€[å¤šå·´èƒº](./../æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine")å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](./../æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine")çš„[é‡Šæ”¾å‰‚](./../æ–‡æ¡£/ç¥ç»é€’è´¨é‡Šæ”¾å‰‚.md "Releasing agent")å’Œ[å†æ‘„å–æŠ‘åˆ¶å‰‚](./../æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Reuptake inhibitor")èµ·ä½œç”¨ã€‚[\[10\]](#cite_note-10)[\[11\]](#cite_note-11) å®ƒè¿˜å…·æœ‰ [5\-HT2A](./../æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")ã€[\[12\]](#cite_note-12) [5\-HT2B](./../æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")ã€[\[13\]](#cite_note-13) å’Œ [5\-HT2C](./../æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")[\[14\]](#cite_note-14) [å—ä½“](./../æ–‡æ¡£/å—ä½“æ¿€åŠ¨å‰‚.md "Receptor") [æ¿€åŠ¨å‰‚](./../æ–‡æ¡£/å—ä½“æ¿€åŠ¨å‰‚.md "Agonist")çš„åŠŸèƒ½ï¼Œå¹¶æ˜¾ç¤ºå‡ºå¯¹ TAAR1ã€Î±2A-ã€Î±2B-ã€Î±2C-è‚¾ä¸Šè…ºç´ å—ä½“å’Œ [5\-HT1A](./../æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin") åŠ [5\-HT7](./../æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin") å—ä½“çš„äº²å’ŒåŠ›ã€‚[\[15\]](#cite_note-15)

å¯¹è¡€æ¸…ç´ çš„å½±å“å¯èƒ½è§£é‡Šäº† [MDMA](./MDMA.md "MDMA") å’Œ MDA è¿™ä¸¤ç§åŒ–åˆç‰©ç›¸ä¼¼çš„[æ¬£å¿«](./../è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md "Euphoria")å’Œ[å…±æƒ…](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogen")æ•ˆåº”ã€‚ç„¶è€Œï¼ŒMDA åœ¨åˆºæ¿€ 5-HT2A [å—ä½“](./../æ–‡æ¡£/å—ä½“æ¿€åŠ¨å‰‚.md "Receptor")æ–¹é¢æ¯” MDMA å…·æœ‰æ›´é«˜çš„æ•ˆåŠ›ï¼›å› æ­¤ï¼ŒMDA å€¾å‘äºå¼•èµ·æ›´å¤šç±»ä¼¼[è¿·å¹»å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Psychedelic")çš„æ•ˆåº”ï¼Œä¾‹å¦‚è§†è§‰[å‡ ä½•å›¾å½¢](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Geometry")å’Œ[å¹»è§‰](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Internal hallucinations")ã€‚è™½ç„¶ MDMA ä¹Ÿèƒ½äº§ç”Ÿç±»ä¼¼è¿·å¹»å‰‚çš„è§†è§‰æ•ˆåº”ï¼Œä½†è¿™äº›æ•ˆåº”ä¸å¦‚ MDA æ˜æ˜¾ï¼Œæˆ–è€…éœ€è¦æ›´å¤§çš„å‰‚é‡æ‰ä¼šå˜å¾—æ˜æ˜¾ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›ç›¸äº’ä½œç”¨çš„ä½œç”¨ä»¥åŠå®ƒä»¬å¦‚ä½•å¯¼è‡´[è¿·å¹»](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Psychedelic")ä½“éªŒä»ç„¶éš¾ä»¥æ‰æ‘¸ã€‚

ä¸»è§‚æ•ˆåº”
------------------

è™½ç„¶ MDA ä¸ [MDMA](./MDMA.md "MDMA") ç›¸ä¼¼ï¼Œä½†ç”¨æˆ·æŠ¥å‘Šè¯´ï¼Œä¸ MDMA ç›¸æ¯”ï¼ŒMDA å…·æœ‰æ›´å¤šçš„[å…´å¥‹å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")å’Œ[è¿·å¹»å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Psychedelic")ç‰¹è´¨ï¼Œè€Œ[å…±æƒ…å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogen")æ•ˆåº”ä¸é‚£ä¹ˆå¼ºçƒˆã€‚MDA ä¹Ÿè¢«è®¤ä¸ºä¸å¦‚ MDMA å®¹æ˜“é¢„æµ‹ï¼Œå…¶æ•ˆåº”å› äººè€Œå¼‚ã€‚

***å…è´£å£°æ˜ï¼š** ä»¥ä¸‹åˆ—å‡ºçš„æ•ˆåº”å¼•ç”¨äº† [***ä¸»è§‚æ•ˆåº”ç´¢å¼•***](./../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md "Subjective effect index") (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºè½¶äº‹ç”¨æˆ·æŠ¥å‘Šå’Œ [FreeODwiki](./../home.md "PsychonautWiki") è´¡çŒ®è€…ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”ä»¥å¥åº·çš„æ€€ç–‘æ€åº¦çœ‹å¾…å®ƒä»¬ã€‚*

*å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡è¾ƒé«˜çš„å‰‚é‡æ›´å¯èƒ½è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚*åŒæ ·ï¼Œ**ä¸è‰¯ååº”**éšç€å‰‚é‡çš„å¢åŠ è€Œå˜å¾—è¶Šæ¥è¶Šå¯èƒ½ï¼Œå¯èƒ½åŒ…æ‹¬ **æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡*** â˜ ã€‚

### **èº¯ä½“æ•ˆåº”**

*     + **[åˆºæ¿€](./../è¯æ•ˆ/åˆºæ¿€.md "Stimulation")** & **[é•‡é™](./../è¯æ•ˆ/é•‡é™.md "Sedation")** - å°±å…¶å¯¹ä½¿ç”¨è€…èº«ä½“èƒ½é‡æ°´å¹³çš„å½±å“è€Œè¨€ï¼ŒMDA é€šå¸¸è¢«è®¤ä¸ºå…·æœ‰çŸ›ç›¾çš„èƒ½åŠ›ï¼Œæ—¢èƒ½åˆºæ¿€åˆèƒ½é•‡é™å’Œæ”¾æ¾ã€‚è™½ç„¶ MDA è¢«æè¿°ä¸ºæ¯” [MDMA](./MDMA.md "MDMA") æ›´â€œå¿«é€Ÿâ€ï¼ˆspeedyï¼‰ï¼Œè¿™å½’å› äºå…¶æ›´é«˜çš„[å¤šå·´èƒº](./../æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine")è½¬è¿è›‹ç™½äº²å’ŒåŠ›ï¼Œ[\[16\]](#cite_note-16) ä½†æ ¹æ®ä¸€ä¸ªäººçš„[æƒ…æ™¯ä¸å¿ƒå¢ƒ](./../æ–‡æ¡£/æƒ…æ™¯ä¸å¿ƒå¢ƒ.md "Set and setting")ï¼Œå®ƒä¹Ÿèƒ½äº§ç”Ÿæ˜æ˜¾çš„é•‡é™â€œçŸ³åŒ–â€ï¼ˆstoningï¼‰æˆ–â€œé”åœ¨æ²™å‘ä¸Šâ€ï¼ˆcouch-lockingï¼‰çš„æ•ˆåº”ã€‚ä¸ MDMA ä¸åŒï¼Œè¿™æ—¢å¯ä»¥é˜»æ­¢ä¹Ÿå¯ä»¥é¼“åŠ±å›¢ä½“ç¤¾äº¤å’Œè·³èˆç­‰æ´»åŠ¨ï¼Œä½¿å…¶æˆä¸ºèŠ‚æ—¥å’Œç‹‚æ¬¢æ´¾å¯¹ç­‰éŸ³ä¹æ´»åŠ¨çš„æµè¡Œç‰©è´¨ã€‚
        - **[èº¯ä½“æ²‰é‡æ„Ÿ](./../è¯æ•ˆ/èº¯ä½“æ²‰é‡æ„Ÿ.md "Perception of bodily heaviness")** - è¿™ä¸ªç»„æˆéƒ¨åˆ†é€šå¸¸ä¼´éšç€è¯¥ç‰©è´¨å¯èƒ½äº§ç”Ÿçš„ä»»ä½•[é•‡é™](./../è¯æ•ˆ/é•‡é™.md "Sedation")æ„Ÿã€‚
        - **[èº¯ä½“è½»ç›ˆæ„Ÿ](./../è¯æ•ˆ/èº¯ä½“è½»ç›ˆæ„Ÿ.md "Perception of bodily lightness")** - è¿™ä¸ªç»„æˆéƒ¨åˆ†é€šå¸¸ä¼´éšç€è¯¥ç‰©è´¨å¯èƒ½äº§ç”Ÿçš„ä»»ä½•[åˆºæ¿€](./../è¯æ•ˆ/åˆºæ¿€.md "Stimulation")æ„Ÿã€‚
    + **[è‡ªå‘æ€§èº¯ä½“æ„Ÿè§‰](./../è¯æ•ˆ/èº¯ä½“æ•ˆåº”.md "Spontaneous physical sensations")** - MDA çš„â€œèº¯ä½“å¿«æ„Ÿâ€ï¼ˆbody highï¼‰å¯ä»¥æè¿°ä¸ºä¸€ç§ä¸­åº¦åˆ°æåº¦æ¬£å¿«çš„åˆºç—›æ„Ÿï¼Œè¾å°„åˆ°å…¨èº«ã€‚åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œå®ƒèƒ½å¤Ÿå˜å¾—ä»¤äººéš¾ä»¥æŠ—æ‹’åœ°æ„‰æ‚¦ï¼Œå¹¶èƒ½å¤Ÿä½¿ä½¿ç”¨è€…æ— æ³•ç§»åŠ¨ã€‚è¿™ç§æ„Ÿè§‰ä¿æŒç€æŒç»­çš„å­˜åœ¨ï¼Œéšç€èµ·æ•ˆç¨³æ­¥ä¸Šå‡ï¼Œä¸€æ—¦è¾¾åˆ°å³°å€¼å³è¾¾åˆ°æé™ã€‚
        - **[èº¯ä½“æ¬£å¿«æ„Ÿ](./../è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md "Physical euphoria")** - æ®æ‚‰ MDA äº§ç”Ÿçš„èº¯ä½“æ¬£å¿«æ„Ÿé€šå¸¸è¢«æè¿°ä¸ºæå…¶æ„‰æ‚¦ï¼Œåœ¨é«˜å³°æœŸåŒ…ç½—ä¸‡è±¡ã€‚
    + **[è§¦è§‰å¢å¼º](./../è¯æ•ˆ/è§¦è§‰æ•ˆåº”.md "Tactile enhancement")** - åœ¨è¿™ç§ç‰©è´¨çš„å½±å“ä¸‹ï¼Œäººä»¬å¯èƒ½ä¼šå‘ç°åœ°æ¯¯ã€æ¯¯å­æˆ–çš®è‚¤ç­‰è¡¨é¢è§¦æ„Ÿæ›´æŸ”è½¯ã€æ›´èˆ’é€‚ã€‚
    + **[èº¯ä½“æ§åˆ¶å¢å¼º](./../è¯æ•ˆ/èº¯ä½“æ§åˆ¶å¢å¼º.md "Bodily control enhancement")**
    + **[è§†ç‰©æŒ¯åŠ¨](./../è¯æ•ˆ/è§†ç‰©æŒ¯åŠ¨.md "Vibrating vision")** - åœ¨é«˜å‰‚é‡ä¸‹ï¼Œäººçš„çœ¼çƒå¯èƒ½ä¼šå¼€å§‹å¿«é€Ÿåœ°æ¥å›æ‘†åŠ¨ï¼Œå¯¼è‡´è§†åŠ›å˜å¾—æ¨¡ç³Šå¹¶æš‚æ—¶å¤±ç„¦ã€‚è¿™æ˜¯ä¸€ç§ç§°ä¸º[çœ¼çƒéœ‡é¢¤](http://en.wikipedia.org/wiki/Nystagmus)çš„æƒ…å†µã€‚
    + **[ä½“æ¸©è°ƒèŠ‚æŠ‘åˆ¶](./../è¯æ•ˆ/ä½“æ¸©è°ƒèŠ‚æŠ‘åˆ¶.md "Temperature regulation suppression")**
        - **[ä½“æ¸©å‡é«˜](./../è¯æ•ˆ/ä½“æ¸©å‡é«˜.md "Increased bodily temperature")** - ç”±äº MDA æ˜¯ä¸€ç§è¡€æ¸…ç´ é‡Šæ”¾å‰‚ï¼Œæ ¸å¿ƒä½“æ¸©å’Œè„‘æ¸©çš„å‡é«˜å¾€å¾€åœ¨æ•´ä¸ªä½“éªŒè¿‡ç¨‹ä¸­ä¿æŒè¾ƒé«˜ä¸”æŒç»­ã€‚å¿…é¡»å°å¿ƒï¼Œå› ä¸ºè¿‡é«˜çš„å‰‚é‡ä¼šå¯¼è‡´å¤§è„‘è°ƒèŠ‚å†…éƒ¨æ ¸å¿ƒæ¸©åº¦çš„èƒ½åŠ›å¤±è°ƒï¼Œä»è€Œå¯¼è‡´[è¡€æ¸…ç´ ç»¼åˆå¾](./../æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")ï¼Œå¦‚æœä¸åŠ ä»¥æ²»ç–—ï¼Œè¿™ç§æƒ…å†µå¯èƒ½æ˜¯è‡´å‘½çš„ã€‚
    + **[è¡€å‹å‡é«˜](./../è¯æ•ˆ/è¡€å‹å‡é«˜.md "Increased blood pressure")**
    + **[å¿ƒç‡å¢å¿«](./../è¯æ•ˆ/å¿ƒç‡å¢å¿«.md "Increased heart rate")**
    + **[å‡ºæ±—å¢åŠ ](./../è¯æ•ˆ/å‡ºæ±—å¢åŠ .md "Increased perspiration")**
    + **[è„±æ°´](./../è¯æ•ˆ/è„±æ°´.md "Dehydration")** - å£å¹²å’Œè„±æ°´çš„æ„Ÿè§‰æ˜¯è¿™ç±»åŒ–åˆç‰©çš„æ™®éä½“éªŒï¼›è¿™ç§æ•ˆåº”æ˜¯[å¿ƒç‡å¢å¿«](./../è¯æ•ˆ/å¿ƒç‡å¢å¿«.md "Increased heart rate")å’Œæ–°é™ˆä»£è°¢å¢åŠ çš„äº§ç‰©ã€‚è™½ç„¶é¿å…è„±æ°´å¾ˆé‡è¦ï¼ˆå°¤å…¶æ˜¯åœ¨ç‚çƒ­çš„ç¯å¢ƒä¸­è·³èˆæ—¶ï¼‰ï¼Œä½†ä¹Ÿæ›¾æœ‰ä¸€äº›è‘—åçš„æ¡ˆä¾‹æ˜¯ç”¨æˆ·å› è¿‡åº¦é¥®æ°´ï¼ˆä¸ºäº†è¡¥å¿ï¼‰è€Œé­å—[æ°´ä¸­æ¯’](./../æ–‡æ¡£/è¯ç‰©è¿‡é‡.md "Water intoxication")ã€‚å› æ­¤ï¼Œå»ºè®®ç”¨æˆ·åªéœ€å°å£å–æ°´ï¼Œé¿å…è¿‡åº¦é¥®æ°´ã€‚
    + **[æ’å°¿å›°éš¾](./../è¯æ•ˆ/æ’å°¿å›°éš¾.md "Difficulty urinating")** - è¾ƒé«˜å‰‚é‡çš„ MDA ä¼šå¯¼è‡´æ’å°¿çš„æ•´ä½“å›°éš¾ã€‚è¿™æ˜¯ä¸€ç§å®Œå…¨æš‚æ—¶ä¸”æ— å®³çš„æ•ˆåº”ã€‚è¿™æ˜¯ç”±äº MDA ä¿ƒè¿›äº†æŠ—åˆ©å°¿æ¿€ç´  (ADH) çš„é‡Šæ”¾ï¼›ADH è´Ÿè´£è°ƒèŠ‚æ’å°¿ã€‚é€šè¿‡ç®€å•çš„æ”¾æ¾å¯ä»¥å‡è½»è¿™ç§æ•ˆåº”ï¼Œä½†åœ¨ç”Ÿæ®–å™¨ä¸Šæ”¾ç½®çƒ­æ¯›å·¾ä½¿å…¶å‡æ¸©å¹¶ä¿ƒè¿›è¯¥åŒºåŸŸçš„è¡€æ¶²æµåŠ¨å¯ä»¥æ˜¾è‘—ç¼“è§£ã€‚
    + **[é£Ÿæ¬²æŠ‘åˆ¶](./../è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md "Appetite suppression")**
    + **[ç³å­”æ‰©å¤§](./../è¯æ•ˆ/ç³å­”æ‰©å¤§.md "Pupil dilation")**
    + **[è¿‡åº¦æ‰“å“ˆæ¬ ](./../è¯æ•ˆ/è¿‡åº¦æ‰“å“ˆæ¬ .md "Excessive yawning")**
    + **[è€åŠ›å¢å¼º](./../è¯æ•ˆ/è€åŠ›å¢å¼º.md "Stamina enhancement")**
    + **[ç£¨ç‰™](./../è¯æ•ˆ/ç£¨ç‰™.md "Teeth grinding")** - è¿™é€šå¸¸åªåœ¨ä¸­åˆ°é«˜å‰‚é‡ä¸‹å‡ºç°ï¼Œç±»ä¼¼äºäººä»¬åœ¨æœç”¨ [MDMA](./MDMA.md "MDMA") æ—¶å¯èƒ½ä½“éªŒåˆ°çš„æƒ…å†µã€‚
    + **[æš‚æ—¶æ€§å‹ƒèµ·åŠŸèƒ½éšœç¢](./../è¯æ•ˆ/æš‚æ—¶æ€§å‹ƒèµ·åŠŸèƒ½éšœç¢.md "Temporary erectile dysfunction")**
    + **[ç™«ç—«å‘ä½œ](./../è¯æ•ˆ/ç™«ç—«å‘ä½œ.md "Seizure")** - è¿™æ˜¯ä¸€ç§ç½•è§çš„æ•ˆåº”ï¼Œä½†å¯èƒ½å‘ç”Ÿåœ¨æ˜“æ„Ÿäººç¾¤ä¸­ï¼Œå°¤å…¶æ˜¯åœ¨æœç”¨è¶…è¿‡æ¨èå‰‚é‡æˆ–å¤„äºèº«ä½“è´Ÿæ‹…è¿‡é‡çš„æƒ…å†µä¸‹ï¼Œå¦‚è„±æ°´ã€ç–²åŠ³æˆ–è¥å…»ä¸è‰¯ã€‚\[*[éœ€è¦å¼•ç”¨]*\]

### **è§†è§‰æ•ˆåº”**

* MDA çš„è§†è§‰æ•ˆåº”å‘ç”Ÿç‡æ¯”ä»»ä½•ä¼ ç»Ÿçš„[è‡´å¹»å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‡´å¹»å‰‚.md "Psychedelics")éƒ½æ›´å…·é€‰æ‹©æ€§ä¸”æ›´ä¸ä¸€è‡´ã€‚è¿™äº›æ•ˆåº”æ°¸è¿œæ— æ³•ä¿è¯æ˜¾ç°ï¼Œä½†åœ¨åŒ–å­¦çº¯åº¦é«˜ã€é«˜å‰‚é‡ MDA ä½“éªŒä¸­ï¼Œåœ¨ä½“éªŒæ¥è¿‘å°¾å£°æ—¶ï¼Œç‰¹åˆ«æ˜¯å¦‚æœä½¿ç”¨è€…ä¸€ç›´åœ¨æŠ½å¸[å¤§éº»](./å¤§éº».md "Cannabis")æ—¶ï¼Œæœ€æœ‰å¯èƒ½å‘ç”Ÿã€‚å¦‚æœä½¿ç”¨è€…ä¹‹å‰æœ‰[è‡´å¹»å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‡´å¹»å‰‚.md "Psychedelics")çš„ç»éªŒï¼Œå®ƒä»¬ä¹Ÿæ›´æœ‰å¯èƒ½å‘ç”Ÿï¼Œä½†å¯¹äºé‚£äº›ä»æœªå°è¯•è¿‡çš„äººæ¥è¯´ä¹Ÿå®Œå…¨å¯èƒ½å‘ç”Ÿã€‚

    ä¸ [MDMA](./MDMA.md "MDMA") ä¸åŒï¼ŒMDA å¯ä»¥ç›´æ¥è¯±å¯¼è½»åº¦è‡³ä¸­åº¦çš„è¿·å¹»è§†è§‰æ•ˆåº”ï¼Œå› ä¸ºå®ƒèƒ½å¤Ÿéƒ¨åˆ†æ¿€åŠ¨ 5HT2A å—ä½“ï¼Œè¿™æ„å‘³ç€å®ƒæœ‰èƒ½åŠ›è¯±å¯¼ä¸­åº¦çš„è¿·å¹»è§†è§‰æ•ˆåº”ã€‚

    #### å¢å¼º
    MDA å‘ˆç°å‡ºä¸€ç³»åˆ—è§†è§‰å¢å¼ºï¼Œä¸ä¼ ç»Ÿè‡´å¹»å‰‚ç›¸æ¯”æ˜¯è½»å¾®çš„ï¼Œä½†ä»ç„¶æ˜æ˜¾å­˜åœ¨ã€‚è¿™äº›é€šå¸¸åŒ…æ‹¬ï¼š

    + **[è§†è§‰é”åº¦å¢å¼º](./../è¯æ•ˆ/è§†è§‰é”åº¦å¢å¼º.md "Visual acuity enhancement")**
    + **[é¢œè‰²å¢å¼º](./../è¯æ•ˆ/é¢œè‰²å¢å¼º.md "Colour enhancement")**
    + **[æ¨¡å¼è¯†åˆ«å¢å¼º](./../è¯æ•ˆ/æ¨¡å¼è¯†åˆ«å¢å¼º.md "Pattern recognition enhancement")**

#### æ‰­æ›²
    + **[æ®‹å½±](./../è¯æ•ˆ/æ®‹å½±.md "Tracers")**
    + **[æ®‹å½±](./../è¯æ•ˆ/æ®‹å½±.md "After images")**
    + **[å¯¹ç§°æ€§çº¹ç†é‡å¤](./../è¯æ•ˆ/è§†è§‰æ‰­æ›².md "Symmetrical texture repetition")**

#### [å‡ ä½•å›¾å½¢](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Geometry")
    è¿™ç§ä½“éªŒä¸­å­˜åœ¨çš„è§†è§‰å‡ ä½•å›¾å½¢å¯ä»¥æè¿°ä¸ºåœ¨å¤–è§‚ä¸Šæ›´ç±»ä¼¼äº[èµ›æ´›è¥¿å®¾](./èµ›æ´›è¥¿å®¾è˜‘è‡.md "Psilocin")è€Œä¸æ˜¯ [LSD](./LSD.md "LSD")ã€‚é€šè¿‡å…¶[å˜ä½“](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Visual effects: Geometry")å¯ä»¥å…¨é¢æè¿°ä¸ºï¼šä¸»è¦æ˜¯å¤æ‚çš„ã€å½¢å¼æŠ½è±¡çš„ã€é£æ ¼æœ‰æœºçš„ã€ç»„ç»‡ç»“æ„çš„ã€å…‰çº¿æ˜æš—çš„ã€é¢œè‰²ä¸»è¦ä¸ºè“è‰²å’Œç°è‰²çš„å•è‰²ã€é˜´å½±æœ‰å…‰æ³½ã€è¾¹ç¼˜é”‹åˆ©ã€å°ºå¯¸å°ã€é€Ÿåº¦å¿«ã€è¿åŠ¨å¹³æ»‘ã€åœ†è§’å’Œå°–è§’ç›¸ç­‰ã€éæ²‰æµ¸å¼æ·±åº¦å’Œå¼ºåº¦ä¸€è‡´ã€‚åœ¨é«˜å‰‚é‡ä¸‹ï¼Œå®ƒä»¬æ›´æœ‰å¯èƒ½å¯¼è‡´[8A çº§](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "8A Geometry")è§†è§‰å‡ ä½•å›¾å½¢è€Œä¸æ˜¯[8B çº§](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "8B Geometry")ã€‚

#### å¹»è§‰çŠ¶æ€
    åœ¨ä¸­åˆ°é‡åº¦å‰‚é‡ä¸‹ï¼ŒMDA èƒ½å¤Ÿäº§ç”Ÿç‹¬ç‰¹èŒƒå›´çš„ä½çº§å’Œé«˜çº§å¹»è§‰çŠ¶æ€ï¼Œå…¶æ–¹å¼æ¯”è®¸å¤šå…¶ä»–å¸¸ç”¨[è‡´å¹»å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‡´å¹»å‰‚.md "Psychedelics")æ›´ä¸ä¸€è‡´ä¸”æ›´éš¾å¤ç°ã€‚è¿™äº›æ•ˆåº”åœ¨ä½“éªŒçš„[è¯æ•ˆè¤ªå»](./../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#è¯æ•ˆè¤ªå» "Duration")æœŸé—´æ›´ä¸ºå¸¸è§ï¼Œé€šå¸¸åŒ…æ‹¬ï¼š

    + **[å‘¨è¾¹ä¿¡æ¯è¯¯åˆ¤](./../è¯æ•ˆ/å‘¨è¾¹ä¿¡æ¯è¯¯åˆ¤.md "Peripheral information misinterpretation")**
    + **[å˜å½¢](./../è¯æ•ˆ/è§†è§‰æ‰­æ›².md "Transformations")**
    + **[å¤–éƒ¨å¹»è§‰](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "External hallucination")** (*[è‡ªä¸»å®ä½“](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Autonomous entities")*; *[è®¾ç½®ã€é£æ™¯å’Œæ™¯è§‚](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Settings, sceneries, and landscapes")*; *[é€è§†å¹»è§‰](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Perspective hallucinations")* å’Œ *[åœºæ™¯å’Œæƒ…èŠ‚](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Scenarios and plots")*) -è¿™ç§æ•ˆåº”éå¸¸ç±»ä¼¼äºåœ¨[è°µå¦„å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è°µå¦„å‰‚.md "Deliriant")ä¸­å‘ç°çš„ä½“éªŒï¼Œä½†ä¸ä¼šä¸€è‡´åœ°æ˜¾ç°ï¼Œé€šå¸¸åªå‘ç”Ÿåœ¨é«˜å‰‚é‡ä¸‹ã€‚é€šè¿‡å…¶[å˜ä½“](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Visual effects: External hallucinations")å¯ä»¥å…¨é¢æè¿°ä¸ºï¼šå¯ä¿¡åº¦ä»¤äººè°µå¦„ã€å¯æ§æ€§è‡ªä¸»ã€é£æ ¼åšå®ã€‚å®ƒä»¬é€šå¸¸éµå¾ªè®°å¿†é‡æ”¾å’ŒåŠç°å®æˆ–é¢„æœŸäº‹ä»¶çš„ä¸»é¢˜ã€‚ä¾‹å¦‚ï¼Œäººä»¬å¯èƒ½ä¼šéšæ‰‹æ‹¿ç€ç‰©ä½“æˆ–åšä¸€äº›ç°å®ç”Ÿæ´»ä¸­æœŸæœ›ä»–ä»¬åšçš„äº‹æƒ…ï¼Œç„¶ååœ¨è¿›ä¸€æ­¥æ£€æŸ¥ä¸‹æ¶ˆå¤±å’Œæº¶è§£ã€‚å¸¸è§çš„ä¾‹å­åŒ…æ‹¬çœ‹åˆ°äººä»¬æˆ´ç€çœ¼é•œæˆ–å¸½å­è€Œå®é™…ä¸Šæ²¡æœ‰ï¼Œå°†æœ‹å‹çš„è„¸è¯¯è®¤ä¸ºæ˜¯é™Œç”Ÿäººï¼Œä»¥åŠå°†ç‰©ä½“è¯¯è®¤ä¸ºæ˜¯äººç±»æˆ–åŠ¨ç‰©ã€‚
    + **[å†…éƒ¨å¹»è§‰](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Internal hallucination")** - MDA è¯±å‘çš„å†…éƒ¨å¹»è§‰å¤§å¤šä»…ä½œä¸ºæé«˜å‰‚é‡ä¸‹çš„è‡ªå‘çªç ´è€Œå­˜åœ¨ã€‚è¿™ç§æ•ˆåº”çš„[å˜ä½“](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Visual effects: Internal hallucinations")æ˜¯ï¼šå¯ä¿¡åº¦ä»¤äººè°µå¦„ã€é£æ ¼äº’åŠ¨ã€å†…å®¹æ˜¯æ–°ä½“éªŒã€å¯æ§æ€§è‡ªä¸»ã€å¤–è§‚åšå®ã€‚å®ƒä»¬æ˜¾ç°çš„æœ€å¸¸è§æ–¹å¼æ˜¯é€šè¿‡ç”¨æˆ·åœ¨ç»è¿‡ä¸€æ™šçš„ä½¿ç”¨åæ¼‚æµè¿›å…¥ç¡çœ æ—¶å¯èƒ½ä½“éªŒåˆ°çš„[å…¥ç¡å‰](./../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Hypnagogic")åœºæ™¯ï¼›è¿™äº›é€šå¸¸å¯ä»¥æè¿°ä¸ºè¿‡å»å‡ ä¸ªå°æ—¶çš„è®°å¿†é‡æ”¾ã€‚è¿™äº›æ˜¯çŸ­æš‚è€Œç¨çºµå³é€çš„ï¼Œä½†é¢‘ç¹ä¸”å®Œå…¨å¯ä¿¡ï¼Œä»¤äººä¿¡æœã€‚å°±ä¸»é¢˜è€Œè¨€ï¼Œå®ƒä»¬é€šå¸¸é‡‡å–ä¸ä½ åœ¨ä¸€èµ·çš„äººäº¤è°ˆçš„å½¢å¼ï¼Œæˆ–è€…è¡¨ç°ä¸ºç¦»å¥‡å’Œæå…¶è’è°¬çš„æƒ…èŠ‚ã€‚

### **è®¤çŸ¥æ•ˆåº”**

* MDA çš„è®¤çŸ¥æ•ˆåº”å¯ä»¥åˆ†è§£ä¸ºå‡ ä¸ªéƒ¨åˆ†ï¼Œéšç€å‰‚é‡çš„å¢åŠ é€æ¸åŠ å¼ºã€‚è®¸å¤šäººå°† MDA çš„ç²¾ç¥çŠ¶æ€æè¿°ä¸ºä¸­åº¦åˆ°æåº¦çš„ç²¾ç¥åˆºæ¿€ã€çˆ±ã€å¼€æ”¾æˆ–åŒç†å¿ƒçš„æ„Ÿè§‰ï¼Œä»¥åŠå¼ºçƒˆçš„æ¬£å¿«æ„Ÿã€‚å®ƒæ˜¾ç¤ºäº†å¤§é‡å…¸å‹çš„[è¿·å¹»å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Psychedelic")ã€[å…±æƒ…å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogenic")å’Œ[å…´å¥‹å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")è®¤çŸ¥æ•ˆåº”ã€‚

    è¿™äº›è®¤çŸ¥æ•ˆåº”ä¸­æœ€çªå‡ºçš„é€šå¸¸åŒ…æ‹¬ï¼š


    + **[ç„¦è™‘æŠ‘åˆ¶](./../è¯æ•ˆ/é•‡é™.md "Anxiety suppression")**
    + **[è®¤çŸ¥æ¬£å¿«æ„Ÿ](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Cognitive euphoria")** - MDA å¯ä»¥äº§ç”Ÿå¼ºçƒˆçš„è®¤çŸ¥æ¬£å¿«æ„Ÿå’Œå¹¸ç¦æ„Ÿï¼Œè¿™å¯èƒ½æ˜¯è¡€æ¸…ç´ å’Œå¤šå·´èƒºé‡Šæ”¾çš„ç›´æ¥ç»“æœã€‚\[*[éœ€è¦å¼•ç”¨]*\]
    + **[åŒç†å¿ƒã€æƒ…æ„Ÿå’Œç¤¾äº¤èƒ½åŠ›å¢å¼º](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Empathy, affection, and sociability enhancement")** - ä¸ä»»ä½•å…¶ä»–å·²çŸ¥ç‰©è´¨ç›¸æ¯”ï¼ŒMDA çš„è¿™ç§ç‰¹å®šæ•ˆåº”æ›´åŠ ä¸€è‡´ã€æ˜æ˜¾ã€å¼ºå¤§ä¸”å…·æœ‰æ²»ç–—ä½œç”¨ã€‚å®ƒæ˜¯ä»»ä½• MDA ä½“éªŒä¸­æœ€æ˜æ˜¾å’Œæœ€å¼•äººæ³¨ç›®çš„æ•ˆåº”ï¼Œå¹¶ä¸»å¯¼ç€ç²¾ç¥çŠ¶æ€ã€‚ç„¶è€Œï¼Œéšç€æ—¶é—´çš„æ¨ç§»ã€é‡å¤ä½¿ç”¨å’Œä¸é€‚å½“çš„é—´éš”ï¼Œè¿™ç§æ•ˆåº”ä¼šä¸¥é‡å‡å¼±ï¼Œå› ä¸ºå…¶çŒè¾“çš„è§‚ç‚¹å˜å¾—å®Œå…¨çƒ™å°åœ¨è„‘æµ·ä¸­ï¼Œä½¿å¾—ç”¨æˆ·æ„Ÿåˆ°ä»…ä»…æ˜¯å¿«é€Ÿå’Œåˆ†æ•£ï¼Œæ²¡æœ‰æ–°å‘ç°çš„ä¸ä»–äººäº¤æµæˆ–ç»“åˆçš„å†²åŠ¨ã€‚
    + **[æƒ…ç»ªå¢å¼º](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Emotion enhancement")**
    + **[æ—¶é—´æ‰­æ›²](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Time distortion")** - æ—¶é—´å‹ç¼©æˆ–æ‰©å¼ çš„å¼ºçƒˆæ„Ÿè§‰åœ¨ MDA ä¸­å¾ˆå¸¸è§ï¼Œå¹¶ç›¸å½“æ˜æ˜¾åœ°æ”¹å˜äº†æ—¶é—´ä½“éªŒã€‚
    + **[å»æŠ‘åˆ¶](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Disinhibition")**
    + **[éŸ³ä¹æ¬£èµå¢å¼º](./../è¯æ•ˆ/å¬è§‰æ•ˆåº”.md "Increased music appreciation")**
    + **[å¹½é»˜æ„Ÿå¢å¼º](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Increased sense of humor")**
        - **[å¤§ç¬‘å‘ä½œ](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Laughter fits")**
    + **[å¼ºè¿«æ€§é‡å¤ç»™è¯](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Compulsive redosing")** - ç”±äºå…¶æ½œåœ¨çš„è¯±å‘æ¬£å¿«æ„Ÿçš„æ•ˆåº”ï¼ŒMDA æœ‰å¯èƒ½é¼“åŠ±å¼ºè¿«æ€§é‡å¤ç»™è¯ï¼Œå°±åƒ MDMA ä¸€æ ·ã€‚ç”±äºä½“éªŒçš„é•¿åº¦ï¼Œè®¸å¤šäººå‘ç°è¿™ä¸ªé—®é¢˜è¾ƒå°ã€‚
    + **[æ–°é¢–æ„Ÿå¢å¼º](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Novelty enhancement")**
    + **[åˆ›é€ åŠ›å¢å¼º](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Creativity enhancement")**
    + **[ä¸“æ³¨åŠ›å¢å¼º](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Focus enhancement")** - è¿™ä¸ªç»„æˆéƒ¨åˆ†åœ¨ä½åˆ°ä¸­ç­‰å‰‚é‡ä¸‹æœ€æœ‰æ•ˆï¼Œå› ä¸ºä»»ä½•æ›´é«˜çš„å‰‚é‡é€šå¸¸ä¼šæŸå®³æ³¨æ„åŠ›ã€‚
    + **[æ²‰æµ¸æ„Ÿå¢å¼º](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Immersion enhancement")**
    + **[åŠ¨æœºå¢å¼º](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Motivation enhancement")**
    + **[æ€§æ¬²å¢å¼º](./../è¯æ•ˆ/æ€§æ¬²å¢å¼º.md "Increased libido")**
    + **[æ­£å¿µ](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Mindfulness")**
    + **[æ€ç»´åŠ é€Ÿ](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought acceleration")**
    + **[æ¸…é†’åº¦](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Wakefulness")** - è¿™ä¸ªç»„æˆéƒ¨åˆ†å­˜åœ¨ï¼Œä½†ç¨‹åº¦æ˜æ˜¾ä½äº [MDMA](./MDMA.md "MDMA")ã€‚ä¸å…¸å‹çš„å…´å¥‹å‰‚ç›¸æ¯”ï¼Œç”¨æˆ·ç»å¸¸æŠ¥å‘Šè¢«ä¸¥é‡é•‡é™æˆ–â€œæ”¾å€’â€ã€‚

### **å¬è§‰æ•ˆåº”**

*     + **[å¢å¼º](./../è¯æ•ˆ/å¬è§‰æ•ˆåº”.md "Auditory enhancement")**
    + **[å¹»è§‰](./../è¯æ•ˆ/å¬è§‰æ•ˆåº”.md "Auditory hallucinations")**
    + **[æ‰­æ›²](./../è¯æ•ˆ/å¬è§‰æ•ˆåº”.md "Auditory distortion")**

### **[è¶…ä¸ªäºº](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Transpersonal")æ•ˆåº”**

*     + **[å­˜åœ¨ä¸»ä¹‰è‡ªæˆ‘å®ç°](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Existential self-realization")** - è™½ç„¶è¿™ç§æ•ˆåº”å­˜åœ¨ï¼Œä½†ä¸å…¶ä»–[è‡´å¹»å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‡´å¹»å‰‚.md "Hallucinogen")å¦‚[éº¦æ–¯å¡æ—](./éº¦æ–¯å¡æ—.md "Mescaline")ã€[LSD](./LSD.md "LSD") æˆ– [MXE](./3-MeO-PCE.md "MXE") ç›¸æ¯”ï¼Œå®ƒä¸é‚£ä¹ˆæ˜æ˜¾æˆ–ä¸€è‡´ã€‚ç„¶è€Œï¼Œç”±äº MDA ç›¸å¯¹äº MDMA å…·æœ‰ç›¸å¯¹çš„å¹³é™å’Œç¼ºä¹æ··ä¹±çš„èƒ½é‡ï¼ŒåŠ ä¸Šå…¶å»¶é•¿çš„æŒç»­æ—¶é—´ï¼Œå¯èƒ½ä½¿å…¶æˆä¸ºæ›´å¥½çš„æ²»ç–—å‰‚ï¼Œå¯ä»¥è®¤ä¸ºæ›´ç±»ä¼¼äº[éº¦æ–¯å¡æ—](./éº¦æ–¯å¡æ—.md "Mescaline")è€Œä¸æ˜¯ [MDMA](./MDMA.md "MDMA")ã€‚
    + **[ç»Ÿä¸€æ„Ÿå’Œç›¸äº’è”ç³»æ„Ÿ](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Unity and interconnectedness")** - 2-3 çº§çš„ç»Ÿä¸€ã€åˆä¸€å’Œç›¸äº’è”ç³»çš„ä½“éªŒåœ¨ MDA ä¸­å¾ˆå¸¸è§ã€‚è¿™ä¸ªç»„æˆéƒ¨åˆ†æœ€ä¸€è‡´åœ°åœ¨é«˜å‰‚é‡ä¸‹çš„å¤§å‹äººç¾¤ä¸­ï¼Œå¦‚ç‹‚æ¬¢æ´¾å¯¹å’ŒéŸ³ä¹æ´»åŠ¨ä¸­ï¼Œä»¥â€œä¸äººç¾¤èä¸ºä¸€ä½“â€çš„å½¢å¼æ˜¾ç°ã€‚

### **è¯æ•ˆæ®‹ä½™**

* å‘ç”Ÿåœ¨[å…´å¥‹å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")ä½“éªŒçš„[è¯æ•ˆè¤ªå»](./../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#è¯æ•ˆè¤ªå» "Offset")æœŸé—´çš„æ•ˆåº”é€šå¸¸æ„Ÿè§‰æ˜¯æ¶ˆæå’Œä¸èˆ’æœçš„ï¼Œè¿™ä¸åœ¨å…¶[è¯æ•ˆè¾¾å³°](./../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#è¯æ•ˆè¾¾å³° "Peak")æœŸé—´å‘ç”Ÿçš„æ•ˆåº”ç›¸æ¯”ã€‚è¿™é€šå¸¸è¢«ç§°ä¸ºâ€œcomedownâ€ï¼Œæ˜¯å› ä¸º[ç¥ç»é€’è´¨](./../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md "Neurotransmitter")è€—å°½è€Œå‘ç”Ÿçš„ã€‚é€šå¸¸è®¤ä¸º MDA çš„ comedown æ¯” [MDMA](./MDMA.md "MDMA") çš„æ›´ä¸¥é…·ã€‚å…¶æ•ˆåº”é€šå¸¸åŒ…æ‹¬ï¼š
    + **[ç„¦è™‘](./../è¯æ•ˆ/ç„¦è™‘.md "Anxiety")**
    + **[é£Ÿæ¬²æŠ‘åˆ¶](./../è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md "Appetite suppression")**
    + **[è„‘ç”µå‡»æ„Ÿ](./../è¯æ•ˆ/è„‘ç”µå‡»æ„Ÿ.md "Brain zaps")** - ä¼—æ‰€å‘¨çŸ¥ï¼Œè¿™ç§æ•ˆåº”å‘ç”Ÿçš„é¢‘ç‡æ¯” [MDMA](./MDMA.md "MDMA") ç•¥é«˜ï¼Œä½†å¦‚æœç”¨æˆ·å®è¡Œé€‚å½“çš„é—´éš”å’Œå®‰å…¨ç»™è¯å®è·µï¼Œé€šå¸¸ä¸ä¼šå‘ç”Ÿã€‚
    + **[è®¤çŸ¥ç–²åŠ³](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Cognitive fatigue")**
    + **[æŠ‘éƒ](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Depression")**
    + **[äººæ ¼è§£ä½“](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Derealization")** - è¿™ç§æ•ˆåº”å¯èƒ½åœ¨å¼ºçƒˆçš„ MDA ä½“éªŒåæš‚æ—¶å‘ç”Ÿï¼Œå¹¶åœ¨æ»¥ç”¨æƒ…å†µä¸‹æŒç»­å­˜åœ¨ã€‚
    + **[åšæ¢¦æŠ‘åˆ¶](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Dream suppression")** *æˆ–* **[åšæ¢¦å¢å¼º](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Dream potentiation")** - è™½ç„¶å·²çŸ¥è¿™ç§ç‰©è´¨ä¼šæŠ‘åˆ¶åšæ¢¦ï¼Œä½†ä¸€äº›ç”¨æˆ·æŒ‡å‡ºï¼Œåœ¨æœç”¨å¤§å‰‚é‡ MDA åçš„å‡ ä¸ªæ™šä¸Šä¼šåšæå…¶å¥‡æ€ªï¼Œæœ‰æ—¶ç”šè‡³å¯æ€•çš„æ¢¦ã€‚
    + **[ç¡çœ ç˜«ç—ª](./../è¯æ•ˆ/èº¯ä½“æ•ˆåº”.md "Sleep paralysis")** - ä¸€äº›ç”¨æˆ·æŠ¥å‘Šæœç”¨ MDA åç»å†ç¡çœ ç˜«ç—ªçš„å‘ç”Ÿç‡è¾ƒé«˜ã€‚
    + **[æ˜“æ€’](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Irritability")**
    + **[åŠ¨æœºæŠ‘åˆ¶](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Motivation suppression")**
    + **[æ€ç»´å‡é€Ÿ](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought deceleration")**
    + **[æ€ç»´è§£ä½“](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought disorganization")**
    + **[è‡ªæ€æ„å¿µ](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Suicidal ideation")** - ä¼—æ‰€å‘¨çŸ¥ï¼Œè¿™ç§æ•ˆåº”å‘ç”Ÿçš„é¢‘ç‡æ¯” [MDMA](./MDMA.md "MDMA") ç•¥é«˜ï¼Œä½†å¦‚æœç”¨æˆ·å®è¡Œé€‚å½“çš„é—´éš”å’Œå®‰å…¨ç»™è¯å®è·µï¼Œé€šå¸¸ä¸ä¼šå‘ç”Ÿã€‚
    + **[æ¸…é†’åº¦](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Wakefulness")**

### ä½“éªŒæŠ¥å‘Š

æè¿°è¯¥åŒ–åˆç‰©åœ¨æˆ‘ä»¬[ä½“éªŒç´¢å¼•](./../æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Experience index")ä¸­çš„æ•ˆåº”çš„è½¶äº‹æŠ¥å‘ŠåŒ…æ‹¬ï¼š

* [Experience:250mg MDA / 250mg MDMA \- unnecessarily large dosage](./æŠ¥å‘Š/psychounautwiki/Experience:250mg_MDA_/_250mg_MDMA_-_unnecessarily_large_dosage.md "Experience:250mg MDA / 250mg MDMA - unnecessarily large dosage")
* [Experience:\~150mg MDA(oral) \- a case of mistaken identity](./æŠ¥å‘Š/psychounautwiki/Experience:~150mg_MDA(oral)_-_a_case_of_mistaken_identity.md "Experience:~150mg MDA(oral) - a case of mistaken identity")


æ›´å¤šçš„ä½“éªŒæŠ¥å‘Šå¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°ï¼š

* [Erowid Experience Vaults: MDA](https://erowid.org/experiences/subs/exp_MDA.shtml)


æ¯’æ€§ä¸å±å®³æ½œåŠ›
---------------------------

æ›´å¤šä¿¡æ¯ï¼š[è´Ÿè´£ä»»çš„ç”¨è¯ Â§ è‡´å¹»å‰‚](./../æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible use")

æ¥è‡ªå°è¯•è¿‡ MDA çš„ç²¾ç¥æ¢ç´¢è€…ç¤¾åŒºçš„è½¶äº‹è¯æ®è¡¨æ˜ï¼Œä»…ä»¥ä½è‡³ä¸­ç­‰å‰‚é‡å°è¯•è¯¥è¯ç‰©å¹¶éå¸¸å°‘é‡åœ°ä½¿ç”¨å®ƒï¼Œæ²¡æœ‰å½’å› äºæ­¤çš„è´Ÿé¢å¥åº·å½±å“ï¼ˆä½†ä¸èƒ½å®Œå…¨ä¿è¯ä»»ä½•äº‹æƒ…ï¼‰ã€‚åœ¨æ¶ˆè´¹ä¹‹å‰ï¼Œåº”å§‹ç»ˆè¿›è¡Œ[ç‹¬ç«‹ç ”ç©¶](https://www.google.com/)ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆæ˜¯å®‰å…¨çš„ã€‚

Harold Blauer[\[17\]](#cite_note-17) äº 1953 å¹´ 1 æœˆåœ¨é™è„‰æ³¨å°„ 450 æ¯«å…‹ MDA åæ­»äº¡ã€‚

ä¼—æ‰€å‘¨çŸ¥ï¼Œä¸ [MDMA](./MDMA.md "MDMA") æˆ– [MDE](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/äºšç”²åŒæ°§åŸºè‹¯ç±»ç‰©è´¨.md "MDE") ç­‰ç‰©è´¨ç›¸æ¯”ï¼ŒMDA å…·æœ‰æ›´å¤§çš„ç¥ç»æ¯’æ€§ã€‚[\[18\]](#cite_note-18)

å¼ºçƒˆå»ºè®®åœ¨ä½¿ç”¨è¿™ç§ç‰©è´¨æ—¶é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](./../æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible drug use")ã€‚

### è€å—æ€§ä¸æˆç˜¾æ½œåŠ›

ä¸å…¶ä»–[å…´å¥‹å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")ä¸€æ ·ï¼Œé•¿æœŸä½¿ç”¨ MDA å¯è¢«è§†ä¸ºå…·æœ‰ä¸­ç­‰æˆç˜¾æ€§ï¼Œå…·æœ‰å¾ˆé«˜çš„æ»¥ç”¨æ½œåŠ›ï¼Œå¹¶èƒ½å¤Ÿå¯¼è‡´æŸäº›ä½¿ç”¨è€…äº§ç”Ÿå¿ƒç†ä¾èµ–ã€‚å½“æˆç˜¾å‘å±•æ—¶ï¼Œå¦‚æœä¸€ä¸ªäººçªç„¶åœæ­¢ä½¿ç”¨ï¼Œå¯èƒ½ä¼šå‘ç”Ÿæ¸´æœ›å’Œ[æˆ’æ–­ååº”](./../æ–‡æ¡£/è¯ç‰©æˆ’æ–­ååº”.md "Withdrawal effects")ã€‚

MDA çš„è¿·å¹»æ•ˆåº”çš„è€å—æ€§å‡ ä¹åœ¨æ‘„å…¥åç«‹å³å»ºç«‹ã€‚ç„¶è€Œï¼Œå…´å¥‹å‰‚å’Œå…±æƒ…å‰‚æ•ˆåº”çš„è€å—æ€§æ˜¯åœ¨é‡å¤å’Œå¤§é‡ä½¿ç”¨åå»ºç«‹çš„ï¼Œå…¶æ–¹å¼å› äººè€Œå¼‚ã€‚ä¹‹åï¼Œéœ€è¦å¤§çº¦ 3 å¤©çš„æ—¶é—´è€å—æ€§å‡åŠï¼Œ7 å¤©æ¢å¤åˆ°åŸºçº¿ï¼ˆåœ¨æ²¡æœ‰è¿›ä¸€æ­¥æ¶ˆè´¹çš„æƒ…å†µä¸‹ï¼‰ã€‚MDA ä¸æ‰€æœ‰[è‡´å¹»å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‡´å¹»å‰‚.md "Psychedelic")å’Œå¤§å¤šæ•°[å…´å¥‹å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")è¡¨ç°å‡ºäº¤å‰è€å—æ€§ï¼Œè¿™æ„å‘³ç€åœ¨æ¶ˆè´¹ MDA åï¼Œæ‰€æœ‰è‡´å¹»å‰‚å’Œä¸€äº›å…´å¥‹å‰‚çš„æ•ˆåº”éƒ½ä¼šé™ä½ã€‚

### å±é™©çš„ç›¸äº’ä½œç”¨

* **[25x\-NBOMe](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/2,5-äºŒç”²æ°§åŸºè‹¯ä¹™èƒºç±»ç‰©è´¨.md "25x-NBOMe") & [25x\-NBOH](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/2,5-äºŒç”²æ°§åŸºè‹¯ä¹™èƒºç±»ç‰©è´¨.md "25x-NBOH")** - 25x åŒ–åˆç‰©å…·æœ‰é«˜åº¦åˆºæ¿€æ€§ä¸”å¯¹èº«ä½“é€ æˆè´Ÿæ‹…ã€‚åº”ä¸¥æ ¼é¿å…ä¸ MDA è”ç”¨ï¼Œå› ä¸ºå­˜åœ¨è¿‡åº¦[åˆºæ¿€](./../è¯æ•ˆ/åˆºæ¿€.md "Stimulation")å’Œå¿ƒè„å‹åŠ›çš„é£é™©ã€‚è¿™å¯èƒ½å¯¼è‡´[è¡€å‹å‡é«˜](./../è¯æ•ˆ/è¡€å‹å‡é«˜.md "Increased blood pressure")ã€[è¡€ç®¡æ”¶ç¼©](./../è¯æ•ˆ/è¡€ç®¡æ”¶ç¼©.md "Vasoconstriction")ã€ææ…Œå‘ä½œã€[æ€ç»´å¾ªç¯](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought loops")ã€[ç™«ç—«å‘ä½œ](./../è¯æ•ˆ/ç™«ç—«å‘ä½œ.md "Seizures")ï¼Œåœ¨æç«¯æƒ…å†µä¸‹ä¼šå¯¼è‡´å¿ƒåŠ›è¡°ç«­ã€‚
* **[é…’ç²¾](./é…’ç²¾.md "Alcohol")** - ç”±äºæ„å¤–è¿‡åº¦ä¸­æ¯’çš„é£é™©ï¼Œå°†é…’ç²¾ä¸[å…´å¥‹å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")ç»“åˆå¯èƒ½æ˜¯å±é™©çš„ã€‚å…´å¥‹å‰‚æ©ç›–äº†é…’ç²¾çš„[æŠ‘åˆ¶å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Depressant")æ•ˆåº”ï¼Œè€Œå¤§å¤šæ•°äººä½¿ç”¨è¿™ç§æ•ˆåº”æ¥è¯„ä¼°ä»–ä»¬çš„ä¸­æ¯’ç¨‹åº¦ã€‚ä¸€æ—¦å…´å¥‹å‰‚æ¶ˆé€€ï¼Œ[æŠ‘åˆ¶å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Depressant")æ•ˆåº”å°†ä¸å†å—é˜»ï¼Œè¿™å¯èƒ½å¯¼è‡´æ–­ç‰‡å’Œä¸¥é‡çš„[å‘¼å¸æŠ‘åˆ¶](./../è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md "Respiratory depression")ã€‚å¦‚æœæ··åˆä½¿ç”¨ï¼Œç”¨æˆ·åº”ä¸¥æ ¼é™åˆ¶æ¯å°æ—¶åªå–ä¸€å®šé‡çš„é…’ç²¾ã€‚
* **[å³ç¾æ²™èŠ¬](./å³ç¾æ²™èŠ¬.md "DXM")** - åº”é¿å…ä¸å³ç¾æ²™èŠ¬è”ç”¨ï¼Œå› ä¸ºå®ƒæŠ‘åˆ¶[è¡€æ¸…ç´ ](./../æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](./../æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine")çš„å†æ‘„å–ã€‚ä¸è¡€æ¸…ç´ é‡Šæ”¾å‰‚ï¼ˆ[MDMA](./MDMA.md "MDMA")ã€[ç”²åŸºé…®](./ç”²å¡è¥¿é…®.md "Methylone")ã€[ç”²æ°§éº»é»„é…®](./4-MMC.md "Mephedrone")ç­‰ï¼‰è”ç”¨æ—¶ï¼Œ[ææ…Œå‘ä½œ](./../è¯æ•ˆ/ç„¦è™‘.md "Panic attacks")å’Œé«˜è¡€å‹å±è±¡æˆ–[è¡€æ¸…ç´ ç»¼åˆå¾](./../æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")çš„é£é™©å¢åŠ ã€‚ä»”ç»†ç›‘æµ‹è¡€å‹å¹¶é¿å…å‰§çƒˆçš„ä½“åŠ›æ´»åŠ¨ã€‚
* **[MDMA](./MDMA.md "MDMA")** - å½“å­˜åœ¨å…¶ä»–[å…´å¥‹å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")æ—¶ï¼ŒMDMA çš„ä»»ä½•ç¥ç»æ¯’æ€§æ•ˆåº”å¯èƒ½ä¼šå¢åŠ ã€‚è¿˜å­˜åœ¨è¿‡åº¦è¡€å‹å’Œå¿ƒè„å‹åŠ›ï¼ˆå¿ƒè„æ¯’æ€§ï¼‰çš„é£é™©ã€‚
* **[MXE](./3-MeO-PCE.md "MXE")** - ä¸€äº›æŠ¥å‘Šè¡¨æ˜ä¸ MXE è”ç”¨å¯èƒ½ä¼šå±é™©åœ°å¢åŠ è¡€å‹å¹¶å¢åŠ [ç‹‚èº](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Mania")å’Œ[ç²¾ç¥ç—…](./../æ–‡æ¡£/å…´å¥‹å‰‚ç²¾ç¥ç—….md "Psychosis")çš„é£é™©ã€‚
* **[è§£ç¦»å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md "Dissociatives")** - è¿™ä¸¤ç±»è¯ç‰©éƒ½å¸¦æœ‰[å¦„æƒ³](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Delusions")ã€[ç‹‚èº](./../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Mania")å’Œ[ç²¾ç¥ç—…](./../æ–‡æ¡£/å…´å¥‹å‰‚ç²¾ç¥ç—….md "Psychosis")çš„é£é™©ï¼Œè”ç”¨æ—¶è¿™ç§é£é™©å¯èƒ½ä¼šå€å¢ã€‚
* **[å…´å¥‹å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")** - MDA ä¸å…¶ä»–[å…´å¥‹å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")å¦‚[å¯å¡å› ](./å¯å¡å› .md "Cocaine")è”ç”¨å¯èƒ½æ˜¯å±é™©çš„ï¼Œå› ä¸ºå®ƒä»¬å¯ä»¥å°†[å¿ƒç‡](./../è¯æ•ˆ/å¿ƒç‡å¢å¿«.md "Increased heart rate")å’Œ[è¡€å‹](./../è¯æ•ˆ/è¡€å‹å‡é«˜.md "Increased blood pressure")æé«˜åˆ°å±é™©æ°´å¹³ã€‚
* **[æ›²é©¬å¤š](./æ›²é©¬å¤š.md "Tramadol")** - å·²çŸ¥æ›²é©¬å¤šä¼šé™ä½ç™«ç—«å‘ä½œé˜ˆå€¼[\[19\]](#cite_note-19)ï¼Œä¸å…´å¥‹å‰‚è”ç”¨å¯èƒ½ä¼šè¿›ä¸€æ­¥å¢åŠ è¿™ç§é£é™©ã€‚
* **[å¯å¡å› ](./å¯å¡å› .md "Cocaine")** - è¿™ç§ç»„åˆå¯èƒ½ä¼šå¢åŠ å¿ƒè„è´Ÿæ‹…ã€‚
* **[è‹¯ä¸™èƒº](./è‹¯ä¸™èƒº.md "Amphetamine")** - è¿™ç§ç»„åˆå¯èƒ½åœ¨é•¿æœŸä½¿ç”¨è‹¯ä¸™èƒºåœæ­¢åäº”å¤©å¼•èµ·è‡ªæ€æ€§ç‹‚èºã€åæ‰§å’Œå¹»è§‰ã€‚è¿™æ˜¯ç”±ç¥ç»ç½‘ç»œä¸å¹³è¡¡å¼•èµ·çš„ï¼Œå¯èƒ½ä¸ MDA ç¼ºä¹é’™é€šé“ä½œç”¨æœ‰å…³ã€‚


#### [è¡€æ¸…ç´ ç»¼åˆå¾](./../æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")é£é™©

ä¸ä»¥ä¸‹ç‰©è´¨è”ç”¨ä¼šå¯¼è‡´å±é™©çš„é«˜[è¡€æ¸…ç´ ](./../æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")æ°´å¹³ã€‚[è¡€æ¸…ç´ ç»¼åˆå¾](./../æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")éœ€è¦ç«‹å³å°±åŒ»ï¼Œå¦‚æœä¸æ²»ç–—å¯èƒ½ä¼šè‡´å‘½ã€‚

* **MAOIs** - ä¾‹å¦‚[å¡çš®æœ¨](./æ­»è—¤æ°´.md "Banisteriopsis caapi")ã€[éª†é©¼è“¬](./æ­»è—¤æ°´.md "Syrian rue")ã€è‹¯ä¹™è‚¼ã€å¸æ¥å‰å…°å’Œå—æ°¯è´èƒºã€‚[\[20\]](#cite_note-20)
* **è¡€æ¸…ç´ é‡Šæ”¾å‰‚** - ä¾‹å¦‚ [MDMA](./MDMA.md "MDMA")ã€[4\-FA](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¸™èƒºç±»ç‰©è´¨.md "4-FA")ã€[ç”²åŸºè‹¯ä¸™èƒº](./ç”²åŸºè‹¯ä¸™èƒº.md "Methamphetamine")ã€[ç”²åŸºé…®](./ç”²å¡è¥¿é…®.md "Methylone")å’Œ [Î±MT](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‰²èƒºç±»ç‰©è´¨.md "Î‘MT")ã€‚
* **SSRIs** - ä¾‹å¦‚è¥¿é…æ™®å…°å’Œèˆæ›²æ—
* **[SNRIs](http://en.wikipedia.org/wiki/SNRIs "wikipedia:SNRIs")** - ä¾‹å¦‚[æ›²é©¬å¤š](./æ›²é©¬å¤š.md "Tramadol")å’Œæ–‡æ‹‰æ³•è¾›
* **5\-HTP**


æ³•å¾‹åœ°ä½
------------

åœ¨å›½é™…ä¸Šï¼ŒMDA æ˜¯ 1971 å¹´ã€Šç²¾ç¥è¯ç‰©å…¬çº¦ã€‹ä¸­çš„é™„è¡¨ I ç‰©è´¨ã€‚[\[21\]](#cite_note-21)

* **æ¾³å¤§åˆ©äºš**: MDA æ˜¯å—æ§ç‰©è´¨ã€‚[\[22\]](#cite_note-22)
* **å¥¥åœ°åˆ©**: æ ¹æ® SMG (Suchtmittelgesetz Ã–sterreich)ï¼ŒæŒæœ‰ã€ç”Ÿäº§å’Œé”€å”® MDA éƒ½æ˜¯è¿æ³•çš„ã€‚\[*[éœ€è¦å¼•ç”¨]*\]
* **åŠ æ‹¿å¤§**: MDA åˆ—äº CSDA çš„é™„è¡¨ I ä¸­ã€‚[\[23\]](#cite_note-23)
* **æ³•å›½**: MDA è¢«åˆ—ä¸º "stupÃ©fiant"ï¼Œå³å…¬è®¤çš„æ»¥ç”¨è¯ç‰©ã€‚æŒæœ‰ã€è´­ä¹°ã€é”€å”®æˆ–åˆ¶é€ éƒ½æ˜¯éæ³•çš„ã€‚[\[24\]](#cite_note-24)
* **å¾·å›½**: æˆªè‡³ 1984 å¹´ 9 æœˆ 1 æ—¥ï¼ŒMDA å— Anlage I BtMGï¼ˆéº»é†‰å“æ³•ï¼Œé™„è¡¨ Iï¼‰ç®¡åˆ¶ã€‚[\[25\]](#cite_note-25)[\[26\]](#cite_note-26) æœªç»è®¸å¯åˆ¶é€ ã€æŒæœ‰ã€è¿›å£ã€å‡ºå£ã€è´­ä¹°ã€é”€å”®ã€è·å–æˆ–åˆ†å‘å®ƒæ˜¯éæ³•çš„ã€‚[\[27\]](#cite_note-27)
* **ä¿„ç½—æ–¯**: MDA è¢«å½’ç±»ä¸ºé™„è¡¨ I è¿ç¦ç‰©è´¨ã€‚[\[28\]](#cite_note-28)
* **ç‘å£«**: MDA æ˜¯ Verzeichnis D ä¸­æ˜ç¡®åˆ—å‡ºçš„å—æ§ç‰©è´¨ã€‚[\[29\]](#cite_note-29)
* **è·å…°**: åœ¨è·å…°ï¼ŒæŒæœ‰ã€ç”Ÿäº§å’Œé”€å”® MDA æ˜¯éæ³•çš„ã€‚[\[30\]](#cite_note-30)
* **è‹±å›½**: MDA æ˜¯ A ç±»è¯ç‰©ã€‚\[*[éœ€è¦å¼•ç”¨]*\]
* **ç¾å›½**: MDA æ˜¯é™„è¡¨ I è¯ç‰©ã€‚[\[31\]](#cite_note-31)


å¦è§
--------

* [è´Ÿè´£ä»»çš„ç”¨è¯](./../æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible use")
* [å…±æƒ…å‰‚](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogen")
* [è‹¯ä¸™èƒº](./è‹¯ä¸™èƒº.md "Amphetamine")
* [MDMA](./MDMA.md "MDMA")
* [MDEA](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/äºšç”²åŒæ°§åŸºè‹¯ç±»ç‰©è´¨.md "MDEA")
* [6\-APB](./../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/äºšç”²åŒæ°§åŸºè‹¯ç±»ç‰©è´¨.md "6-APB")


å¤–éƒ¨é“¾æ¥
--------------

* [MDA (Wikipedia)](https://en.wikipedia.org/wiki/3,4-Methylenedioxyamphetamine)
* [MDA (Erowid Vault)](https://www.erowid.org/chemicals/mda/mda.shtml)
* [MDA (PiHKAL / Isomer Design)](https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=100)
* [MDA (DrugBank)](https://go.drugbank.com/drugs/DB01509)


æ–‡çŒ®
----------

* Green, A.J., Mechan, A.O., Elliott, J.M., O'shea, E., \& Colado, M.I. (2003\). The pharmacology and clinical pharmacology of 3,4\-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacological Reviews, 55 3, 463\-508\. <https://doi.org/10.1124/pr.55.3.3>


å‚è€ƒæ–‡çŒ®
----------

1. â†‘ [1\.0](#cite_ref-Mannich1910_1-0) [1\.1](#cite_ref-Mannich1910_1-1) Mannich, C., Jacobsohn, W., Mannich, C. (January 1910\). ["Ãœber Oxyphenylâ€alkylamine und Dioxyphenylâ€alkylamine"](https://onlinelibrary.wiley.com/doi/10.1002/cber.19100430126). *Berichte der deutschen chemischen Gesellschaft*. **43** (1\): 189â€“197\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1002/cber.19100430126](//doi.org/10.1002%2Fcber.19100430126). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0365\-9496](//www.worldcat.org/issn/0365-9496).Â 
2. [â†‘](#cite_ref-2) Schoenfeld, Eugene. "Hippocrates". Berkeley Barb November 24\-30, 1967: 7 (Independent Voices) \| <http://voices.revealdigital.com/cgi-bin/independentvoices?a=d&d=BFBJFGD19671124.1.7>
3. [â†‘](#cite_ref-3) [\[1\]](https://pubmed.ncbi.nlm.nih.gov/7582557/)
4. [â†‘](#cite_ref-4) [*$700,000 Awarded to Estate of Army Drug Test Victim*](https://www.latimes.com/archives/la-xpm-1987-05-06-mn-2486-story.html), 1987Â 
5. [â†‘](#cite_ref-5) "Methylenedioxy Amphetamine (MDA)." Microgram. Bureau of Drug Abuse Control. Feb 1968\. 1(5\):4\-5 (Erowid.org) \| <https://erowid.org/library/periodicals/microgram/microgram_1968_02_v01n05.pdf>
6. [â†‘](#cite_ref-6) Power, Mike (2 May 2013\). *Drugs 2\.0: The Web Revolution That's Changing How the World Gets High*. Portobello Books Ltd. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number")Â [9781846274596](http://en.wikipedia.org/wiki/Special:BookSources/9781846274596 "wikipedia:Special:BookSources/9781846274596").Â 
7. [â†‘](#cite_ref-7) Naranjo, C., Shulgin, A. T., Sargent, T. (1967\). ["Evaluation of 3,4\-Methylenedioxyamphetamine (MDA) as an Adjunct to Psychotherapy"](https://www.karger.com/Article/FullText/137100). *Pharmacology*. **17** (4\): 359â€“364\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1159/000137100](//doi.org/10.1159%2F000137100). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0031\-7012](//www.worldcat.org/issn/0031-7012).Â 
8. [â†‘](#cite_ref-8) Yensen, R., Di Leo, F. B., Rhead, J. C., Richards, W. A., Soskin, R. A., Turek, B., Kurland, A. A. (October 1976\). "MDA\-assisted psychotherapy with neurotic outpatients: a pilot study". *The Journal of Nervous and Mental Disease*. **163** (4\): 233â€“245\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1097/00005053\-197610000\-00002](//doi.org/10.1097%2F00005053-197610000-00002). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0022\-3018](//www.worldcat.org/issn/0022-3018).Â }}
9. [â†‘](#cite_ref-9) Baggott, M. J., Siegrist, J. D., Galloway, G. P., Robertson, L. C., Coyle, J. R., Mendelson, J. E. (2 December 2010\). ["Investigating the Mechanisms of Hallucinogen\-Induced Visions Using 3,4\-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans"](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0014074). *PLOS ONE*. **5** (12\): e14074\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1371/journal.pone.0014074](//doi.org/10.1371%2Fjournal.pone.0014074). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1932\-6203](//www.worldcat.org/issn/1932-6203).Â 
10. [â†‘](#cite_ref-10) Lewin, A. H., Miller, G. M., Gilmour, B. (1 December 2011\). "Trace amine\-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class". *Bioorganic \& Medicinal Chemistry*. **19** (23\): 7044â€“7048\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1016/j.bmc.2011\.10\.007](//doi.org/10.1016%2Fj.bmc.2011.10.007). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1464\-3391](//www.worldcat.org/issn/1464-3391).Â 
11. [â†‘](#cite_ref-11) Wallach, J. V. (January 2009\). "Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception". *Medical Hypotheses*. **72** (1\): 91â€“94\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1016/j.mehy.2008\.07\.052](//doi.org/10.1016%2Fj.mehy.2008.07.052). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0306\-9877](//www.worldcat.org/issn/0306-9877).Â 
12. [â†‘](#cite_ref-12) Giovanni, G. D., Matteo, V. D., Esposito, E. (11 November 2008\). *Serotonin\-Dopamine Interaction: Experimental Evidence and Therapeutic Relevance*. Elsevier. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number")Â [9780444532350](http://en.wikipedia.org/wiki/Special:BookSources/9780444532350 "wikipedia:Special:BookSources/9780444532350").Â 
13. [â†‘](#cite_ref-13) Rothman, R. B., Baumann, M. H. (May 2009\). "Serotonergic drugs and valvular heart disease". *Expert Opinion on Drug Safety*. **8** (3\): 317â€“329\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1517/14740330902931524](//doi.org/10.1517%2F14740330902931524). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1744\-764X](//www.worldcat.org/issn/1744-764X).Â 
14. [â†‘](#cite_ref-14) Nash, J. F., Roth, B. L., Brodkin, J. D., Nichols, D. E., Gudelsky, G. A. (15 August 1994\). "Effect of the R(\-) and S(\+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5\-HT2A or 5\-HT2C receptors". *Neuroscience Letters*. **177** (1â€“2\): 111â€“115\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1016/0304\-3940(94\)90057\-4](//doi.org/10.1016%2F0304-3940%2894%2990057-4). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0304\-3940](//www.worldcat.org/issn/0304-3940).Â 
15. [â†‘](#cite_ref-15) Ray, T. S. (2 February 2010\). "Psychedelics and the human receptorome". *PloS One*. **5** (2\): e9019\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1371/journal.pone.0009019](//doi.org/10.1371%2Fjournal.pone.0009019). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1932\-6203](//www.worldcat.org/issn/1932-6203).Â 
16. [â†‘](#cite_ref-16) Johnson, M. P., Hoffman, A. J., Nichols, D. E. (December 1986\). ["Effects of enantiomers of MDA, MDMA and related analogues on \[3H\]serotonin and \[3H\]dopamine release from superfused rat brain slices"](https://linkinghub.elsevier.com/retrieve/pii/0014299986906151). *European Journal of Pharmacology*. **132** (2â€“3\): 269â€“276\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1016/0014\-2999(86\)90615\-1](//doi.org/10.1016%2F0014-2999%2886%2990615-1). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0014\-2999](//www.worldcat.org/issn/0014-2999).Â 
17. [â†‘](#cite_ref-17) The History Channel documented details of his death here <http://www.youtube.com/watch?v=ySw-0uY4CUA> See minute 2:38 onward.
18. [â†‘](#cite_ref-18) <https://web.archive.org/web/20130518010439/http://www.drogen-info-berlin.de/htm/mda.html>
19. [â†‘](#cite_ref-19) Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009\). "Dose\-independent occurrence of seizure with tramadol". *Journal of Medical Toxicology*. **5** (2\): 63â€“67\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1007/BF03161089](//doi.org/10.1007%2FBF03161089). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number")Â [1937\-6995](//www.worldcat.org/issn/1937-6995). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1556\-9039](//www.worldcat.org/issn/1556-9039). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC")Â [163567183](//www.worldcat.org/oclc/163567183).Â 
20. [â†‘](#cite_ref-20) Gillman, P. K. (2005\). ["Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity"](https://bjanaesthesia.org/article/S0007-0912(17)34956-5/fulltext). *British Journal of Anaesthesia*. **95** (4\): 434â€“441\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1093/bja/aei210](//doi.org/10.1093%2Fbja%2Faei210)â€¯![Freely accessible](https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/langen-gb-20px-Lock-green.svg.png "Freely accessible"). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number")Â [1471\-6771](//www.worldcat.org/issn/1471-6771). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0007\-0912](//www.worldcat.org/issn/0007-0912). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC")Â [01537271](//www.worldcat.org/oclc/01537271). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier")Â [16051647](//www.ncbi.nlm.nih.gov/pubmed/16051647).Â 
21. [â†‘](#cite_ref-21) ["CONVENTION ON PSYCHOTROPIC SUBSTANCES 1971"](http://www.emcdda.europa.eu/system/files/attachments/10451/convention_1971_en.pdf) (PDF). United Nations. Retrieved December 15, 2019.Â 
22. [â†‘](#cite_ref-22) ["Criminal Code Regulations 2019"](https://www.legislation.gov.au/Details/F2019L00561). Office of Parliamentary Counsel. Retrieved December 15, 2019.Â 
23. [â†‘](#cite_ref-23) ["Controlled Drugs and Substances Act \- SCHEDULE I"](https://www.laws-lois.justice.gc.ca/eng/acts/C-38.8/page-13.html#docCont). Government of Canada. Retrieved December 15, 2019.Â 
24. [â†‘](#cite_ref-24) [*ArrÃªtÃ© du 22 fÃ©vrier 1990 fixant la liste des substances classÃ©es comme stupÃ©fiants*](https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/2020-11-20/)Â 
25. [â†‘](#cite_ref-25) ["Erste Verordnung zur Ã„nderung betÃ¤ubungsmittelrechtlicher Vorschriften"](https://www.bgbl.de/xaver/bgbl/start.xav#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl184s1081.pdf%27%5D__1576029878276) (in German). Bundesanzeiger Verlag. Retrieved December 15, 2019.Â 
26. [â†‘](#cite_ref-26) ["Anlage I BtMG"](https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html) (in German). Bundesministerium der Justiz und fÃ¼r Verbraucherschutz. Retrieved December 15, 2019.Â 
27. [â†‘](#cite_ref-27) ["Â§ 29 BtMG"](https://www.gesetze-im-internet.de/btmg_1981/__29.html) (in German). Bundesministerium der Justiz und fÃ¼r Verbraucherschutz. Retrieved December 15, 2019.Â 
28. [â†‘](#cite_ref-28) [*Resolution of the Government of the Russian Federation*](https://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=314201&fld=134&dst=100034,0&rnd=0.41568319511755825#047741519652799347)Â 
29. [â†‘](#cite_ref-29) ["Verordnung des EDI Ã¼ber die Verzeichnisse der BetÃ¤ubungsmittel, psychotropen Stoffe, VorlÃ¤uferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html) (in German). Bundeskanzlei \[Federal Chancellery of Switzerland\]. Retrieved January 1, 2020.Â 
30. [â†‘](#cite_ref-30) Koninkrijksrelaties, M. van B. Z. en, [*Opiumwet*](https://wetten.overheid.nl/BWBR0001941/2020-01-01)Â 
31. [â†‘](#cite_ref-31) Passie, T., BenzenhÃ¶fer, U. (June 2016\). "The History of MDMA as an Underground Drug in the United States, 1960\-1979". *Journal of Psychoactive Drugs*. **48** (2\): 67â€“75\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1080/02791072\.2015\.1128580](//doi.org/10.1080%2F02791072.2015.1128580). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0279\-1072](//www.worldcat.org/issn/0279-1072).